Pakistan Veterinary Journal

ISSN: 0253-8318 (PRINT), 2074-7764 (ONLINE)
DOI: 10.29261/pakvetj/2023.034

REVIEW ARTICLE

Fasciolosis: Recent Update in Vaccines Development and Their Efficacy

Tauseef ur Rehman[1*], Fahmy Gad Elsaid[2], Maria Magdalena Garijo Toledo[3], Arcangelo Gentile[4], Riaz Ahmed Gul[1], Muhammad Rashid[1], Muhammad Tahir Aleem[5,6] and Muhammad Arfan Zaman[7]

[1]Department of Parasitology, The Islamia University of Bahawalpur, Pakistan
[2]Biology Department, College of Science, King Khalid University, Asir, Abha, Al-Faraa, P.O. Box: 960-Postal Code: 61421, Saudi Arabia; [3]Department of Animal Production and Health, Public Veterinary Health and Food Science and Technology, Faculty of Veterinary Medicine, Universidad Cardenal Herrera-CEU, CEU Universities. Calle Tirant lo Blanc, 7, 46115, Valencia, Spain; [4]Department of Veterinary Medical Sciences, University of Bologna, Italy
[5]MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, P.R. China; [6]Center for Gene Regulation in Health and Disease, Department of Biological, Geological, and Environmental Sciences, College of Sciences and Health Professions, Cleveland State University, Cleveland, OH 44115, USA
[7]Department of Pathobiology, College of Veterinary and Animal Sciences, Jhang
*Corresponding author: drtauseef@iub.edu.pk

ARTICLE HISTORY (23-053)

Received: February 25, 2023
Revised: May 19, 2023
Accepted: May 25, 2023
Published online: May 27, 2023

Key words:
Control
Efficacy
Fasciolosis
Immune response
Vaccine development

A B S T R A C T

Fasciolosis is caused by *F. hepatica* and *F. gigantica*. It is of economic and zoonotic importance. Several strategies for control of fasciolosis are being used; these include vaccination of animals that are at risk and control of the snails that carry the parasite. Several types of vaccines, such as recombinant cathepsin, mixed recombinant vaccine, fatty-acid-binding proteins, a cocktail of recombinant and fatty-acid-binding vaccines, nucleic acid-based vaccines and gene-silencing methods have been reported to show efficacy ranges of 32-75%, 52-79%, 8-36%, 43-68%, 74-100% and 90% respectively. These are currently undergoing experimental testing against fasciolosis. The study described in this paper was carried out to discover the comparative efficacy of these vaccines in the enhancement of the immune response in order to find the most effective method so that future research could focus on the development of that type of vaccine. Besides immunization, control of the intermediate host of the parasite (snail) is also an effective way to control fasciolosis. Snails are controlled through the use of physical, chemical and biological methods. The most effective of these is biological control using *Sphaerodema urinator* as a predator of snails.

To Cite This Article: Rehman TU, Elsaid FG, Toledo MMG, Gentile A, Gul RA, Rashid M, Aleem MT and Zaman MA, 2023. Fasciolosis: recent update in vaccines development and their efficacy. Pak Vet J, 43(2): 224-231. http://dx.doi.org/10.29261/pakvetj/2023.034

1. Introduction

Fasciolosis is an emerging zoonotically important disease in several (>70) countries (Mehmood *et al.,* 2017; Webb and Cabada, 2018). It is a food-borne disease that is caused by the parasitic trematodes *F. hepatica* and *F. gigantica* (El-Rahimy *et al.,* 2012). Infectious diseases cause serious threat to economy of livestock industry (Abbas *et al.,* 2021). Among infectious diseases, helminths pose high impact in terms of mortality, reduction in meat, milk and quality of hides. Fasciolosis leads losses worth an estimated cost of US$3 billion each year around the world to livestock industry (Piedrafita *et al.,* 2010; Mehmood *et al.,* 2017; McManus, 2020; Villa-Mancera *et al.,* 2021; Zafra *et al.,* 2021). It has been mentioned that Fasciolosis increases the mortality rate and decreases the production at domestic level and had serious effect on country economics (Dar *et al.,* 2005). It has been reported that about 180 million people are at risk of infection with food-borne zoonotic diseases and of them between 35-72 million are infected with fasciolosis (Cwiklinski *et al.,* 2016; Rehman *et al.,* 2016; Sabourin *et al.,* 2018). The rate of *Fasciola* infection depends upon the climate in which the potential infected lives, agricultural practices and the level of resistance that the parasites have developed against antitrematode drugs (Kelly *et al.,* 2016; Rehman *et al.,* 2016). Snails (*Lymnaea auricularia* var rufescens and *Lymnaea auricularia* var stricto) are the intermediate host of *Fasciola*. They are

prevalent in tropical and temperate zones (Lalrinkima *et al.*, 2021). They reported that *Radix natalensis* (*Lymnaea natalensis*) also plays an important role in the transmission of *F. gigantica* (Dar *et al.*, 2005). It was reported that another species of snails like *Galba truncatula* (*L. truncatula*) is prevalent in Egypt and helps in transmission of parasite while other species like *Pseudosuccinea columella* (*L. columella*) and *Biomphalaria alexandrina* (Planorbidae) normally found habituating larvae of *Fasciola* sp. (Dar *et al.*, 2005). *F. hepatica* is prevalent in cold and temperate climate while *F. gigantica* is prevalent in tropical and subtropical countries whereas both species often mixed n subtropical areas (Zaman *et al.*, 2014). Unembryonated eggs passed in feces hatch in water into miracidia after embryonation. Miracidia penetrate intermediate host snails and molt into sporocysts, rediae and cercariae. Cercariae then come out of snails and encyst into metacercariae which are ingested by ruminant host. Metacercariae then excyst in duodenum and travel through liver to reach bile duct as shown in Fig. 1. Fasciolosis can be controlled by the application of antitrematode treatment to diseased animals and by restricting the size of the snail population. Variations in methods of antitrematode treatment in terms of dose rate according to efficacy and breed ultimately result in the development of drug resistance (Fairweather, 2011; Hanna *et al.*, 2015), which could lead to an alarming situation both now and in the future. Therefore, an effective vaccine must be produced in order to control fasciolosis infection (Dalton *et al.*, 2013; Dominguez *et al.*, 2018). Several recombinant, attenuated, subunit, cocktail, kunitz-type and nucleic-acid-based vaccines have been trialed in organisms to assess their enhancement of the hosts' immune responses to fasciolosis. The protection level achieved by these vaccines remains low (Toet *et al.*, 2014; Molina-Hernández *et al.*, 2015; Beesley *et al.*, 2018; Lalrinkima *et al.*, 2021). In this review article, we highlight and compare the several kinds of vaccines that have been studied to find out which offers the best method for the control of fasciolosis.

2. Epidemiology of fasciolosis

The prevalence of fasciolosis is dependent on climatic conditions and whether the regions in which the animals live are tropical or temperate (Lalrinkima *et al.*, 2021). It has been reported that, in tropical and sub-tropical areas, fasciolosis is more prevalent in the rainy season in small ruminant as opposed to large ruminants (Bauri *et al.*, 2015; Swarnkar *et al.*, 2021). Similarly, it has been reported that the occurrence of infection by liver flukes (as the parasites are known) increases during and after the monsoon season but falls in the winter (Bauri *et al.*, 2015). The density of snails is correlated with the rate of fasciolosis infection after the monsoon when the raised water temperature and rainy weather lead to an increase in the number of snails and a direct increase in disease transmission (Silvane *et al.*, 2020). Fasciolosis is a zoonotically important disease; the World Health Organization (WHO) has reported that approximately 2.4 million people are infected (Ashdhir *et al.*, 2014). Diagnostic evidence of fluke in the bile duct and their ova in the stool have been reported (Brockwell *et al.*, 2014; Ramanan *et al.*, 2019).



Fig. 1. Life of cycle of *Fasciola hepatica* in ruminants.

3. Vaccines against fasciolosis

In ruminants and humans, fasciolosis is caused by *F. hepatica* and *F. gigantica* (Dalton *et al.,* 2013). The infection has vast geographical distribution and affects the health of both farmers and livestock (Cooper *et al.,* 2012). Indiscriminate use of medication such as the anthelmintic triclabendazole, which is the drug of choice to treat this disease, has led to drug resistance in the parasites and the build-up of drug residues in meat and the environment (Piedrafita *et al.,* 2004; Fairweather *et al.,* 2011; Hanna *et al.,* 2015; Silvane *et al.,* 2020). This worrying situation highlights the urgency to producing an effective vaccine that can be used to control fasciolosis in animals including humans. Several studies have been conducted to enhance humoral or cell-mediated immunity to fasciolosis due to immunization with attenuated, recombinant, gene knockdown/silencing, or, nucleic-acid-based vaccines, or a cocktail of these (McManus *et al.,* 2006; Spithill *et al.,* 2012). The immunogenic efficacy of each method is summarized here to discover the most effective type of vaccine. Efficacy of mixed recombinant vaccine against fasciolosis infection is shown in Table 1.

3.1. Attenuated vaccines: The simplest way to produce a vaccine is through attenuation (irradiation and culturing) of a pathogen so that its pathogenic properties are eliminated. A whole pathogen contains several kinds of antigens which act as a source of an infection, so a vaccine that exhibits immune reaction to variety of antigens, is considered to provide better protection than other vaccines. However, the chances of the occurrence of allergic reactions to the vaccine in animals are much greater than when other vaccines (Golden *et al.,* 2010; Tadesse *et al.,* 2021). Use of irradiated metacercariae of *F. hepatica* can help us to control the number of flukes as well as development of infection, damage to liver and concentration of glutamate dehydrogenase and γ-Glutamyl transferase (Nansen, 1975). Metacercariae of *F. hepatica* attenuated with γ irradiation level of 3 Krad conferred significant resistance to calves through reduction in worm count and fecundity (Khan *et al.,* 2017).

3.2. Excretory/ secretory product vaccines: Excretory/ secretory (ES) products of *Fasciola* has immunogenic properties and can be used in immunodiagnosis and vaccine production. Polypeptide profiling of ES products of *F. gigantica* identified 24 polypeptide epitopes among which 12 epitopes were found to be immunogenic (El-Ridi *et al.,* 2007). ES product molecules exhibited considerable immunogenic response eliciting interleukin-12p40 mRNA response and production of good quantity of antibodies which bind to surface molecules of newly excysted juvenile worms. Cellular and humoral response induced by ES products result in moderate reduction of number of worms, however size of recovered worms is significantly reduced (Di Maggio *et al.,* 2019). Intermediate host species influence the immunogenic proteomic response of host. Immunogenic response to juveniles of *F. hepatica* derived from different snail species significantly differs (Kalita *et al.,* 2019) with difference in protein modification machinery, protease inhibitors, signal transduction, and cysteine-rich proteins.

3.2. Recombinant vaccine

3.2.1. Cathepsin proteins: The main *Fasciola* spp. protein classes that have been evaluated in vaccination trials are cathepsin B, cathepsin L, leucyl aminopeptidase, thioredoxin glutathione reductase, fatty-acid-binding protein-1 (FABP-1), saposin-like protein-2 and 14–3-3 protein epsilon) (Caffrey *et al.,* 2018). Several native and recombinant proteins have been identified as potential candidates for vaccine production against fasciolosis infection. Cathepsins (cathepsin L and cathepsin L mimotopes) are proteases. They are expressed abundantly in the liver fluke as they aid in tissue invasion by the parasite (Maggioli *et al.,* 2011; Cwiklinski *et al.,* 2019). Cathepsin L mimotopes (CL1 (DPWWLKQ), CL1 (SGTFLFS) and CL2 (PPIRNGK)) have been used in the control of fasciolosis infection in goats. These proteases have been used to decrease the liver-fluke burden (Molina-Hernández *et al.,* 2015). These researchers reported that the use of cathepsin L mimotopes caused a significant decrease (32.39-70.42%) in the egg burden laid by the liver fluke (Table 1). Moreover, it was found that goats treated with CL1 and CL2 mimotopes produced humoral and cellular immunity against the parasite (Th1/Th2), and the titers of antibodies (immunoglobulin G (IgG)1 and IgG2) increased four weeks after vaccination (Molina-Hernández *et al.,* 2015; Shaukat *et al.,* 2019). It has been reported that haemoglobin, cathepsin (L1 and L2) and leucine aminopeptidase of *F. hepatica* have been used collectively to control fasciolosis infection. After the use of this mixed vaccine (cathepsin L1 and L2 with haemoglobin), the researchers found a significant decrease in the liver fluke burden up to 53.7% (Dar *et al.,* 2005). Similarly, another study reported a 98% anti-embryonated effect on eggs after the use of CL2 and haemoglobin of *F. hepatica* (Haçarız *et al.,* 2012). Similar findings reported that the production of a mixed multiepitope vaccine (cathepsins L and B, leucine aminopeptidase, saposin-like protein-2, thioredoxin glutathione reductase and FABP) showed a good immunogenic effect against fasciolosis infection (Caffrey *et al.,* 2018). Efficacy of recombinant cathepsin (cathepsin L and cathepsin L mimotopes) proteins vaccine is shown in Table 1.

3.2.2. Fatty-acid-binding protein: Parasite extract or recombinant antigens can be used to control fasciolosis infection (Haçarız *et al.,* 2012). *Fasciola* cannot synthesize long-chain fatty acids or steroids, which are usually produced by the beta-oxidation pathway (López-Abán *et al.,* 2008). Yet FABPs are very important for the survival of liver fluke, and therefore the parasite depends on the host for FABP supply (López-Abán *et al.,* 2007). In studies, the supply of native and recombinant FABPs in sheep and cattle led to control of fasciolosis up to 55% (Nambi *et al.,* 2005; López-Abán *et al.,* 2007). Recombinant FgFABP was used with Freund's adjuvant; vaccinated animals showed both humoral and cell-mediated immunity with a reduced (35.8%) chance of fasciolosis infection in buffalo (Varghese *et al.,* 2010; Lalrinkima *et al.,* 2021). Another study also reported that the use of FgFABP by cell-penetrating peptides (R-19, R-22 and R-25) obtained from infectious bursal disease virus triggered an immune response (Th1 and Th2), which was

evidenced by increased levels of immunoglobulins (IgG1, IgG2α and IgG2β) and cytokines (IFN, TNF, IL-2, IL-4 and IL-5) (Bozas *et al.*, 1995). Efficacy of Fatty-acid-binding protein type of vaccine is shown in Table 1.

Table 1: Efficacy of recombinant cathepsin proteins, Mixed recombinant vaccine, Fatty-acid-binding protein (FABP) and Cocktail vaccine

Parasite	Host	Immunization with	Adjuvant	Type of Response	Vaccine	Decrease Worn Load (%) or Efficacy (%)	Reference(s)
F. hepatica	Cattle	rCL	------	IgG1 & IgG2	Recombinant Cathepsin Proteins	37	(Garcia-Campos *et al.*, 2019) (Tadesse *et al.*, 2012)
		rCL	------	IgG1 & IgG2		48	
	Goat	rCL	------	IgG & IgG1		38	(Buffoni *et al.*, 2012) (Pérez-Écija *et al.*, 2010) (Dominguez *et al.*, 2018) (Villa-Mancera *et al.*, 2021)
		rCL	------	No response		39	
		FhPrx	------	------		33	
		CL1 (DPWWLKQ)	------	Th1/Th2 (IgG1 & IgG2)		55	
		CL1 (SGTFLFS)	------	Th1/Th2 (IgG1 & IgG2)		70	
		CL2 (PPIRNGK)	------	------		32	
	Sheep	FhCL2	------	------		34	(Dominguez *et al.*, 2018)
	Rat	recombinant FhCL3-2	------	Th1/Th2 (IgG1 & IgG2a)		53	(Wesołowska *et al.*, 2018)
F. hepatica adult excretion/ secretion	Sheep	CL1 + CL2 + LAP	FCA/FIA	------	Mixed recombinant vaccine	79	(Dominguez *et al.*, 2018)
		CL1 + CL2	FCA/FIA	------		60	
	Cattle	CL1 + Hb	FCA/FIA	------		51	
		CL2 + Hb	FCA/FIA	------		72	
F. gigantica	Mice	recombinant proFgCatL1H	------	Th1/Th2 (IgG1 & IgG2a)	Recombinant Cathepsin Proteins	66	(Sansri *et al.*, 2015) (Changklungmoa *et al.*, 2016) (Kueakhai *et al.*, 2021)
		recombinant mature FgCatL1G	------			58	
		FgCatL1H and FgCatB3	------			75	
F. hepatica or F. gigantica	Mice	FABP	DNA + mannosylated-polyethylenimine	Elevation of Th1 cytokines	Fatty-acid-binding protein		(Lalrinkima *et al.*, 2021)
		FABP	DNA + cell-penetrating peptide	Elevation of Th1/Th2 cytokines		------	
		FABP	DNA + polyethylenimine	No protection		------	
	Buffalo	Recombinant FABP and glutathione S-transferase	Montanide 70 M-VG	------		35.8	
		Recombinant leucine aminopeptidases and peroxiredoxin	Montanide 70 M-VG	------		8.4	
		rFABP	Freund's adjuvant	------		35.8	
	Cattle and sheep	Native and rFABP	Freund's adjuvant	Humeral and cell mediated immunity	Fatty-acid-binding protein	35.8	(Brockwell *et al.*, 2014)
		recombinant FgFABPs	Freund's adjuvant	Humeral and cell mediated immunity			(Ramanan *et al.*, 2019)
	Sheep (Group A)	Recombinant-CL1 + recombinant-HDM + recombinant-LAP + recombinant-Prx	Montanide	------	Cocktail vaccine	42	(Zafra *et al.*, 2021)
	Sheep (Group B)	recombinant-CL1 + recombinant-HDM + recombinant-LAP + recombinant-Prx	Alhydrogel	------		58	
	Sheep (Group C)	Positive control	-----	------		67	
F. hepatica	Sheep (Group1)	Irradiated metacercariae of *F. hepatica* with Irradiation dose of 30 grays	Gelatin Capsule	Humoral response	Attenuated Vaccine	18.6	(Trelis *et al.*, 2022)
	Sheep (Group2)	Irradiated metacercariae of *F. hepatica* with Irradiation dose of 60 grays	Gelatin Capsule	Humoral response	Attenuated Vaccine	13.4	
	Sheep (Group3)	Irradiated metacercariae of *F. hepatica* with Irradiation dose of 120 γ rays	Gelatin Capsule	Humoral response	Attenuated Vaccine	11.2	
	Sheep (Group4)	Irradiated metacercariae of *F. hepatica* with Irradiation dose of 240 γ rays	Gelatin Capsule	Humoral response	Attenuated Vaccine	7.7	
	Infected control	------	------	------	------	22.5	

rCL1 = *F. hepatica* recombinant cathepsin; rHDM = *F. hepatica* recombinant helminths defence molecule; rLAP = *F. hepatica* recombinant leucine aminopeptidase; rPrx = *F. hepatica* recombinant peroxiredoxin.

3.2.3. *F. hepatica* Kunitz-type molecule: *F. hepatica* Kunitz-type molecules (FhKTM) are used as antigens (Silvane *et al.,* 2020). FhKTM is a single polypeptide of 58 amino acids. It is present in large quantity in gut, parenchymal tissue and tegument of adult *F. hepatica* (Mulcahy *et al.,* 1998). Apart from this abundance, this molecule is potent inhibitor of proteases and best suit as vaccine candidate (Silvane *et al.,* 2020). They are formulated by liquid crystal nanostructure with the assembly of a 6-O-ascorbyl palmitate ester (Coa-ASC16) and a synthetic oligodeoxynucleotide that contains unmethylated cytosine-guanine motifs (CpG-ODN) for vaccine production against *F. hepatica* (Silvane *et al.,* 2020). The molecules enhance the humoral immune response against *F. hepatica* (Cervi *et al.,* 2004; Toet *et al.,* 2014; Fracasso *et al.,* 2017). Studies have reported that the introduction of FhKTM/CpG-ODN/Coa-ASC16 increases the production of interleukin (IL)-17A and interferon-gamma (IFNγ), which are effective in the control of the fasciolosis infection (Lin *et al.,* 2009; Falcón *et al.,* 2012). It has also been reported that vaccination with FhKTM/CpG-ODN/Coa-ASC16 prevents liver damage and improves the survival of the host (Silvane *et al.,* 2020). Similarly, other studies have reported that IFNγ and IL-17A work synergistically by initiating the production of nitric oxide in macrophages to provide protection against *Fasciola* infection (Kumar *et al.,* 2012; Nascimento *et al.,* 2015; Gao *et al.,* 2016).

3.3. Cocktail vaccine: For successful migration and development in the host, liver flukes require the expression of multiple genes including FgFABP and Fg-glutathione S-transferase through the use of mountainside 70M-VG adjuvant or a delivery agent (Spithill *et al.,* 2012). The use of a cocktail vaccine that incorporates both of these genes triggers the IgG1 and IgG2 antibody responses and hyper-eosinophilia, which has been shown to provide protection upto 35% in animals (Kofta *et al.,* 2000). A diverse combination of recombinant vaccines includes *F. hepatica* recombinant cathepsin L1 (rCL1), *F. hepatica* recombinant peroxiredoxin (rPrx), *F. hepatica* recombinant helminths defense molecule (rHDM) and *F. hepatica* recombinant leucine aminopeptidases (rLAP) in two different (Montanide and Alhydrogel) adjuvants. The results shown in Table 1 indicate that a certain level of protection has been achieved against *F. hepatica* with the help of rCL1, rHDM, rPrx, rLAP and Montanide ISA 61 VG (Zafra *et al.,* 2021). Efficacy of Cocktail vaccine is shown in Table 1.

3.4. Nucleic-acid vaccines: Nucleic-acid vaccines against fasciolosis infection offer an advanced vaccine production technique that has eliminated the difficulties associated with recombinant vaccines (Carmona *et al.,* 1993). It has been found that cysteine proteases are crucial in host-parasite interactions (Carmona *et al.,* 1993) as they play a major role in migration, protection of the parasite from the host immune system and the feeding of *Fasciola* (Smitha *et al.,* 2010). One study has reported that the use of naked FgFABP DNA with nosylated-polyethylenimine-FgFABP shows significant production of Th1 cytokines (IFN-γ and tumor necrosis factor) in mice and these protect the host against the parasitic infection as shown in Fig. 2 (Kofta *et al.,* 2000). Cysteine proteases with complementary DNA vaccination have been found to provide 100% protection against liver fluke infection (Kaplan, 2001) in male mice and 74% protection in females (Carmona *et al.,* 1993; Kofta *et al.,* 2001). Briefly, 50µg of complementary DNA cysteine proteases in 250µl of saline was mixed with 0.05% bupivacaine (Carmona *et al.,* 1993), and this vaccine blocked the parasite at an early stage of life; evidence came from the eosinophil range and rate of liver damage in mice (Anderson *et al.,* 1997; Waine *et al.,* 1997).

3.5. Vector control: Control of intermediate hosts that support any parasitic infection is the best choice to eradicate diseases caused by the parasite. There are physical, chemical and biological processes that can be used to control hosts. Physical control methods include reducing the snail population through environmental management (elimination of water bodies, hu-man settlement, effective drainage, and rotation of aquatic and xeromorphic crops) (Leighton *et al.,* 2000; Li *et al.,* 2016; Bajwa *et al.,* 2022).



Fig. 2: Mechanism of nanoparticle vaccine. APC = Antigen presenting cells (Dendritic cells), TCR = T cell receptor, TIRAP = Toll-interleukin-1 receptor domain containing adaptor protein, MHC = Major histocompatibility complex, TLR = Toll-like receptor.

Chemical control involves the use of either natural or synthetic chemicals (molluscicides). The application of these chemicals remains an efficient method for the control of snails (Xia *et al.,* 2014). Synthetic chemicals such as N-tritylmorpholine, copper sulfate, niclosamide, sodium pentachlorophenol, bromoacetamide and nicotinamide were used to control snails in Africa, Asia, China and South America from the 1950s to 1970s (King *et al.,* 2015; Liu *et al.,* 2021; Hussain *et al.,* 2021). Among these synthetic molluscicides, only niclosamide is recommended by the WHO; however, it is expensive and toxic to aquatic animals. Therefore, a 50% wettable powder of niclosamide ethanolamine salt (WPN) is used in China, where it is the only synthetic compound available to eradicate snails and is widely used (Carmona *et al.,* 1993; Kofta et al 2001; Akram *et al.,* 2019). To overcome these challenges, a novel molluscicide, a quinoid-2′, 5-dichloro4′-nitrosalicylanilide salt, has been

developed that has the same molluscicidal effects as WPN but is cheaper and significantly less toxic to fish (Kofta *et al.,* 2000). Another new molluscicide (niclosamide suspension concentrate) is more effective, more stable and less toxic than WPN (King *et al.,* 2015). Due to high cost, toxicity and resistance and environmental contamination caused by chemical molluscicides, natural molluscicides produced from several kinds of environment friendly plant extracts are also used (Lu *et al.,* 2018). Biological control involves the use of environmentally acceptable living organisms to kill the target/harmful organism. Examples of these organisms include prawns, water bugs and *Sphaerodema urinator*. They share the habitat of freshwater snails and control their numbers (Leighton *et al.,* 2000; Lu *et al.,* 2018). Biological control is mutually beneficial to nature, including humans (Xia *et al.,* 2014).

4. Future perspective

The development of a vaccine against fasciolosis infection poses a major challenge to the scientific community due to the various life stages of the parasite that must be controlled in the host. As yet there is insufficient knowledge of immunogenic proteins to produce vaccines against the parasite. Further studies are required regarding the changes that occur in the structure of the reproductive organs of liver flukes after vaccination. The cock-tail vaccine is a good choice but the interaction between the antigen in the multivalent vaccine and fasciolosis is not yet properly understood. According to this review of various studies, the maximum protection rate was found after vaccination with cysteine protease cDNA, which was reported to provide 100% protection in male mice and 74% in females. However, further trials in cattle are required. An important challenge in vaccine production against *F. hepatica* is the Th2-type of immunosuppressive response, which may hamper efforts to eliminate the parasite. Moreover, proteins in the parasite gut, parenchymal tissue and the tegument of juvenile and adult parasites act as protease inhibitors, which protect the parasite from the destruction of the tissue that it must penetrate.

Conclusions: Genus *Fasciola* comprises two-host (snail and mammals) trematode parasites. It is of zoonotic importance. Resistance to the drugs that have been used to control parasitic infection has become a major challenge. To combat this problem, researchers are focused on the development of vaccines to eradicate fasciolosis. Most parasites undergo several life stages in a host, which reduces the efficacy of vaccines. Researchers have developed several kinds of vaccines in laboratories that show variable efficacy. Fasciolosis is hepatobiliary disease in which major damage is caused by migrating juveniles of liver fluke and indirectly by host immune response to ES products of *Fasciola* resulting in host's tissue damage. In most cases, efficacy of a vaccine is judged by reduction in number of worms reaching bile duct examined in postmortem examination of experimental animals. However at this stage, liver damage cannot be easily graded. Hence, importance should be given to parameters quantifying liver damage at early stage i.e., damage caused during migration of newly excysted juveniles. Most effective vaccine would be one directed against newly excysted juveniles and their ES products with aim of preventing penetration of liver capsule by juveniles. Among all types of vaccines currently under investigation, the review found that RNA silencing and nucleic-acid vaccines significantly reduced infection rates in vaccinated animals, by 89.6 and 74-100% respectively. Additionally, control of the intermediate (snail) host has also proved to be an effective way to eradicate fasciolosis in endemic areas.

Authors contributions: Writing-original draft: TUR, FGE, RAG; Writing-review & editing: MR, FGE, MMGT, MTA, AG, MAZ Conceptualization: TUR. All authors have read and agreed to the published version of the manuscript.

Acknowledgments: The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through large group Research Project under grant number RGP2/12/44.

Conflicts of Interest: The authors declare that there is no conflict of interest regarding the publication of this article.

REFERENCES

Abbas J, Azam S and Bhutta ZA, 2021. Molecular, pharmacological, and biochemical approaches: The latest panacea for emerging viral diseases. Continental Vet J 1:9-19.

Akram MZ, Zaman MA, Jalal H, *et al.,* 2019. Prevalence of gastrointestinal parasites of captive birds in Punjab, Pakistan. Pak Vet J 39:132-4.

Anderson R, Gao XM, Papakonstantinopoulou A, *et al.,* 1997. Immunization of mice with DNA encoding fragment C of tetanus toxin. Vaccine 15:827-9.

Ashdhir P, Sharma SS and Sharma G, 2014. Biliary colic with dilated common bile duct: simple" sheepish" problem? J Indian Med Assoc 112:122-3.

Bajwa HUR, Khan MK, Abbas Z, *et al*., 2022. Nanoparticles: Synthesis and their role as potential drug candidates for the treatment of parasitic diseases. Life 12:750.

Bauri RK, Chandra D, Lalrinkima H, *et al.,* 2015. Epidemiological studies on some trematode parasites of ruminants in the snail intermediate hosts in three districts of Uttar Pradesh, Jabalpur and Ranchi. Indian J Anim Sci 85:941-6.

Beesley NJ, Caminade C, Charlier J, *et al.,* 2018. *Fasciola* and fasciolosis in ruminants in Europe: Identifying research needs. Transbound Emerg Dis 65:199-216.

Brockwell YM, Elliott TP, Anderson GR, *et al.,* 2014. Confirmation of *Fasciola hepatica* resistant to triclabendazole in naturally infected Australian beef and dairy cattle. Int J Parasitol: Drugs Drug Resist 4:48-54.

Buffoni L, Martínez-Moreno FJ, Zafra R, *et al.,* 2012. Humoral immune response in goats immunised with cathepsin L1, peroxiredoxin and Sm14 antigen and experimentally challenged with *Fasciola hepatica*. Vet Parasitol 185:315–21.

Caffrey CR, Goupil L, Rebello KM, *et al.,* 2018. Cysteine proteases as digestive enzymes in parasitic helminths. PLOS Negl Trop Dis 12:0005840.

Carmona C, Dowd AJ, Smith AM, *et al.,* 1993. Cathepsin L proteinase secreted by *Fasciola hepatica* in vitro prevents antibody-mediated eosinophil attachment to newly excysted juveniles. Mol Biochem Parasitol 62:9-17.

Cervi L, Borgonovo J, Egea M, *et al.,* 2004. Immunization of rats against *Fasciola hepatica* using crude antigens conjugated with Freund's adjuvant or oligodeoxynucleotides. Vet Immunol Immunopathol 97:97-104.

Changklungmoa N, Phoinok N, Yencham C, *et al.,* 2016. Vaccine potential of recombinant cathepsinL1G against *Fasciola gigantica* in mice. Vet Parasitol 226:124–31.

Cooper KM, Kennedy DG and Danaher M, 2012. ProSafeBeef and anthelmintic drug residues-a case study in collaborative application

of multi-analyte mass spectrometry to enhance consumer safety. Anal Bioanal Chem 404:1623-30.

Cwiklinski K, Donnelly S, Drysdale O, *et al.,* 2019. The cathepsin-like cysteine peptidases of trematodes of the genus *Fasciola*. Adv Parasitol 104:113-64.

Cwiklinski K, O'neill SM, Donnelly S, *et al.,* 2016. A prospective view of animal and human Fasciolosis. Parasite Immunol 38:558-68.

Dalton JP, Robinson MW, Mulcahy G, *et al.,* 2013. Immunomodulatory molecules of *Fasciola hepatica*: candidates for both vaccine and immunotherapeutic development. Vet Parasitol 195:272-85.

Dar YD, Rondelaud D and Dreyfuss G, 2005. Update of fasciolosis-transmitting snails in Egypt (review and comment). J Egypt Soc Parasitol 35:1.

Dominguez MF, González-Miguel J, Carmona C, *et al.,* 2018. Low allelic diversity in vaccine candidates genes from different locations sustain hope for *Fasciola hepatica* immunization. Vet Parasitol 258:46-52.

El-Rahimy HH, Mahgoub AM, El-Gebaly NSM, *et al.,* 2012. Molecular, biochemical, and morphometric characterization of *Fasciola* species potentially causing zoonotic disease in Egypt. Parasitol Res 111:1103-11.

Fairweather I, 2011. Raising the bar on reporting 'triclabendazole resistance'. Vet Rec 168:514-5.

Falcón CR, Carranza FA, Aoki P, *et al.,* 2012. Adoptive transfer of dendritic cells pulsed with *Fasciola hepatica* antigens and lipopolysaccharides confers protection against fasciolosis in mice. J Infec Dis 205:506-14.

Fracasso M, Da Silva AS, Baldissera MD, *et al.,* 2017. Activities of ectonucleotidases and adenosine deaminase in platelets of cattle experimentally infected by *Fasciola hepatica*. Exp Parasitol 176:16-20.

Gao Q, Liu Y, Wu Y, *et al.,* 2016. IL-17 intensifies IFN-γ-induced NOS2 upregulation in RAW 264.7 cells by further activating STAT1 and NF-κB. Intern J Mol Med 37:347-58.

Garcia-Campos A, Correia CN, Naranjo-Lucena A, *et al.,* 2019. *Fasciola hepatica* infection in cattle: Analyzing responses of peripheral blood mononuclear cells (PBMC) using a transcriptomics approach. Front Immunol 10: doi:10.3389/FIMMU.2019.02081/FULL

Golden O, Flynn RJ, Read C, *et al.,* 2010. Protection of cattle against a natural infection of *Fasciola hepatica* by vaccination with recombinant cathepsin L1 (rFhCL1). Vaccine 28:5551-7.

Haçarız O, Sayers G and Baykal AT, 2012. A proteomic approach to investigate the distribution and abundance of surface and internal *Fasciola hepatica* proteins during the chronic stage of natural liver fluke infection in cattle. J Proteome Res 11:3592-04.

Hanna REB, McMahon C, Ellison S, *et al.,* 2015. *Fasciola hepatica*: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology. Vet Parasitol 207:34-43.

Hussain K, Abbas RZ, Abbas A, *et al.,* 2021. Anticoccidial and biochemical effects of *Artemisia brevifolia* extract in broiler chickens. Braz J Poultry Sci 23:1-6.

Kalita P, Lyngdoh DL, Padhi AK, *et al.,* 2019. Development of multi-epitope driven subunit vaccine against *Fasciola gigantica* using immunoinformatics approach. Int J Biol Macromol 138:224-33.

Kaplan RM, 2001. Fasciola hepatica: a review of the economic impact in cattle and considerations for control. Vet Ther 2:40-50.

Khan MAH, Ullah R, Rehman A, *et al.,* 2017. Immunolocalization and immunodetection of the excretory/secretory (ES) antigens of *Fasciola gigantica*. PLoS ONE 12:e0185870. https://doi.org/10.1371/journal.pone.0185870

King CH, Sutherland LJ and Bertsch D, 2015. Systematic review and meta-analysis of the impact of chemical-based mollusciciding for control of *Schistosoma mansoni* and *S. haematobium* transmission. PLoS Negl Trop Dis 9:e0004290.

Kofta W and Wedrychowicz H, 2001. c-DNA vaccination against parasitic infections: advantages and disadvantages. Vet Parasitol 100:3-12.

Kofta W, Mieszczanek J, Płucienniczak G, *et al.,* 2000. Successful DNA immunisation of rats against fasciolosis. Vaccine 18:2985-90.

Kueakhai P, Changklungmoa N, Cheukamud W, *et al.,* 2021. The combined recombinant cathepsin L1H and cathepsin B3 vaccine against *Fasciola gigantica* infection. Parasitol Int 83: doi:10.1016/J.PARINT.2021.102

Kumar N, Anju V, Gaurav N, *et al.,* 2012. Vaccination of buffaloes with *Fasciola gigantica* recombinant glutathione S-transferase and fatty acid binding protein. Parasitol Res 110:419-26.

Lalrinkima H, Lalchhandama C, Jacob SS, *et al.,* 2021. Fasciolosis in India: an overview. Exp Parasitol:108066.

Leighton BJ, Zervos S and Webster JM, 2000. Ecological factors in schistosome transmission, and an environmentally benign method for controlling snails in a recreational lake with a record of schistosome dermatitis. Parasitol Int 49:9-17.

Li ZJ, Ge J, Dai JR, *et al.,* 2016. Biology and control of snail intermediate host of Schistosoma ja-ponicum in the People's Republic of China. Adv Parasitol 92:197-236.

Lin Y, Ritchea S, Logar A, *et al.,* 2009. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31:99-810.

Liu B, Li Y, Mehmood K, *et al.,* 2021. Role of oxidative stress and antioxidants in hiram-induced tibial dyschondroplasia. Pak Vet J 41:1-6.

López-Abán J, Casanueva P, Nogal J, *et al.,* 2007. Progress in the development of *Fasciola hepatica* vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD. Vet Parasitol 145:287-96.

López-Abán J, Nogal-Ruiz JJ, Vicente B, *et al.,* 2008. The addition of a new immunomodulator with the adjuvant adaptation ADAD system using fatty acid binding proteins increases the protection against *Fasciola hepatica*. Vet Parasitol 153:176-81.

Di Maggio LS, Tirloni L, Pinto AFM, 2019. A proteomic comparison of excretion/secretion products in *Fasciola hepatica* newly excysted juveniles (NEJ) derived from *Lymnaea viatrix* or *Pseudosuccinea columella*. Exp Parasitol 201:11–20.

Lu XT, Gu QY, Limpanont Y, *et al.,* 2018. Snail-borne parasitic diseases: an update on global epidemiological distribution, transmission interruption and control methods. Infectious Dis Poverty 7:1-16.

Maggioli G, Acosta D, Silveira F, *et al.,* 2011. The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against *Fasciola hepatica* infection in sheep. Vaccine 29:9057-63.

McManus DP and Dalton JP, 2006. Vaccines against the zoonotic trematodes Schistosoma japonicum, *Fasciola hepatica* and *Fasciola gigantica*. Parasitol 133:S43-S61.

McManus DP, 2020. Recent progress in the development of liver fluke and blood fluke vaccines. Vaccines 8:553.

Mehmood K, Zhang H, Sabir AJ, *et al.,* 2017. A review on epidemiology, global prevalence and economical losses of fasciolosis in ruminants. Micro Path 109:253-62.

Molina-Hernández V, Mulcahy G, Pérez J, *et al.,* 2015. *Fasciola hepatica* vaccine: we may not be there yet but we're on the right road. Vet Parasitol 208:101-11.

Mulcahy G, O'Connor F, McGonigle S, *et al.,* 1998. Correlation of specific antibody titre and avidity with protection in cattle immunized against *Fasciola hepatica*. Vaccine 16:932-9.

Nambi PA, Yadav SC, Raina OK, *et al.,* 2005. Vaccination of buffaloes with *Fasciola gigantica* recombinant fatty acid binding protein. Parasitol Res 97:129-35.

Nansen P, 1975. Resistance in cattle to *Fasciola hepatica* induced by γ-ray attenuated larvae: results from a controlled field trial. Res Vet Sci 19:278-83.

Nascimento MSL, Carregaro V, Lima-Júnior DS, *et al.,* 2015. Interleukin 17A acts synergistically with interferon γ to promote protection against Leishmania infantum infection. J infec Dis 211:1015-26.

Pérez-Écija RA, Mendes RE, Zafra R, *et al.,* 2010. Pathological and parasitological protection in goats immunised with recombinant cathepsin L1 and challenged with *Fasciola hepatica*. Vet J (London, England: 1997 185:351–3, doi:10.1016/J.TVJL.2009.07.004.

Piedrafita D, Raadsma HW, Prowse R, *et al.,* 2004. Immunology of the host–parasite relationship in fasciolosis (*Fasciola hepatica* and *Fasciola gigantica*). Canadian J Zool 82:233-50.

Piedrafita D, Spithill TW, Smith RE, *et al.,* 2010. Improving animal and human health through understanding liver fluke immunology. Parasite Immunol 32:572-81.

El Ridi R, Salah M, Wagih A, *et al.,* 2007. *Fasciola gigantica* excretory–secretory products for immunodiagnosis and prevention of sheep fasciolosis. Vet Parasitol 149:219-28.

Ramanan RV, Dhus U, Ramamurthy A, *et al.,* 2019. Human fascioliasis: Diagnosis by typical computed tomography features and response to nitazoxanide in 16 patients from India. Trop Gastroenterol 39:149-54.

Rehman T, Khan MN, Abbas RZ, *et al.,* 2016. Serological and coprological analyses for the diagnosis of *Fasciola gigantica*

infections in bovine hosts from Sargodha, Pakistan. J Helminthol 90:494-502.

Bozas SE, Panaccio M, Creaney J, *et al.,* 1995. Characterisation of a novel Kunitz-type molecule from the trematode *Fasciola hepatica*, Mol Biochem Parasitol 74:19-29

Sabourin E, Alda P, Vázquez A, *et al.,* 2018. Impact of human activities on fasciolosis transmission. Trends Parasitol 34:891-903.

Sansri V, Meemon K, Changklungmoa N, *et al.,* 2015. Protection against *Fasciola gigantica* infection in mice by vaccination with recombinant juvenile-specific cathepsin L. Vaccine 33:1596-601.

Shaukat A, Medmood K, Shaukat I, *et al.,* 2019. Prevalence, haematological alterations and chemotherapy of bovine anaplasmosis in Sahiwal and Crossbred cattle of district Faisalabad, Punjab, Pakistan. Pak J Zool 51:2023-32.

Silvane L, Celias DP, Romagnoli PA, *et al.,* 2020. A Vaccine Based on Kunitz-Type Molecule Confers Protection Against *Fasciola hepatica* Challenge by Inducing IFN-γ and Antibody Immune Responses through IL-17A production. Front Immunol 11:2087.

Smitha S, Raina OK, Singh BP, *et al.,* 2010. Immune responses to polyethylenimine-mannose-delivered plasmid DNA encoding a *Fasciola gigantica* fatty acid binding protein in mice. J Helminth 84:149-55.

Spithill TW, Carmona C, Piedrafita D, *et al.,* 2012. Prospects for immunoprophylaxis against *Fasciola hepatica* (liver fluke). Parasitic Helminths: Targets, Screens, Drugs and Vaccines pp:465-84.

Swarnkar CP, Khan FA and Singh D, 2021. Prevalence of fluke infestation in sheep flocks of Rajasthan, India. Bio Rhythm Res 52:645-53.

Tadesse A, Eguale T, Ashenafi H, *et al.,* 2021. Enzymatic and fecundity evaluation of *Fasciola hepatica* exposed to different doses of γ-irradiation in Ethiopian sheep. Ethiopian Vet J 25:85-114.

Toet H, Piedrafita DM and Spithill TW, 2014. Liver fluke vaccines in ruminants: strategies, progress and future opportunities. Int J Parasitol 44:915-27.

Trelis M, Sanchez-Lopez CM, Sanchez-Palencia LF, *et al.,* 2022. Proteomic Analysis of Extracellular Vesicles from *Fasciola hepatica* Hatching Eggs and Juveniles in Culture. Front Cell Infect Microbiol 12:903602.

Varghese A, Raina OK, Kumar S, *et al.,* 2010. A cell penetrating peptide in the delivery of plasmid DNA encoding *Fasciola gigantica* fatty acid binding protein in mice. J Vet Parasitol 24:173-9.

Villa-Mancera A, Alcalá-Canto Y, Olivares-Pérez J, *et al.,* 2021. Vaccination with cathepsin L mimotopes of *Fasciola hepatica* in goats reduces worm burden, morphometric measurements, and reproductive structures. Microb Path 155:104859.

Waine GJ, Yang W, Scott JC, *et al.,* 1997. DNA-based vaccination using *Schistosoma japonicum* (Asian blood-fluke) genes. Vaccine 15:846-8.

Webb CM and Cabada MM, 2018. Recent developments in the epidemiology, diagnosis, and treatment of *Fasciola* infection. Curr Opin Infec Dis 31:409-14.

Wesołowska A, Basałaj K, Norbury LJ, *et al.,* 2018. Vaccination against *Fasciola hepatica* using cathepsin L3 and B3 proteases delivered alone or in combination. Vet Parasitol 250:15-21.

Xia J, Yuan Y, Xu X, *et al.,* 2014. Evaluating the effect of a novel molluscicide in the endemic schistosomiasis japonica area of China. Int J Environ Res Public Health 11:10406-18.

Zafra R, Buffoni L, Pérez-Caballero R, *et al.,* 2021. Efficacy of a multivalent vaccine against *Fasciola hepatica* infection in sheep. Vet Res 52:1-9.

Zaman MA, Sajid M, Sikandar A, *et al.,* 2014. Point prevalence of gastrointestinal helminths and their association with sex and age of buffaloes in lower Punjab, Pakistan. Int J Agric Biol 16(6).